Investor Presentaiton
142
Investor presentation Full year 2022
Solid sales growth driven by Diabetes and Obesity care
DKK billion
Reported annual sales 2018-2022
+12%1
14%
15%
16%
16%
12%
88%
86%
84%
85%
84%
2018
2019
2020
Rare disease
2021
Diabetes and Obesity care
1 CAGR for 5-year period
S&D: Sales and distribution; R&D: Research and development
Note: The outlined expected developments are aspirations and not long-term financial targets
2022
السمر
لام
Expected development towards 2025
Gross margin
Remain broadly stable
Novo NordiskⓇ
S&D cost ratio
Gradually decline enabled by
attractive sales growth
R&D cost ratio
8
88
Administration
cost ratio
Gradually increase to
expand and diversify pipeline
Decline driven by efficiency
gains
Operating
margin
Remain broadly stableView entire presentation